Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tranexamic acid
Drug ID BADD_D02261
Description Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.[L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Indications and Usage Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema,[L31883] cyclic heavy menstrual bleeding in premenopausal females,[L31858] and other instances of significant bleeding in the context of hyperfibrinolysis.[L31883] Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.[L31853]
Marketing Status approved
ATC Code B02AA02
DrugBank ID DB00302
KEGG ID D01136
MeSH ID D014148
PubChem ID 5526
TTD Drug ID D05HXX
NDC Product Code 51927-0022; 73309-178; 42571-189; 50268-772; 69918-301; 70771-1085; 0591-3720; 49452-7876; 51552-0513; 81999-0001; 82920-038; 70121-1398; 23155-524; 43066-008; 55150-188; 63629-8838; 67850-041; 68083-160; 71335-1981; 60505-6169; 65145-106; 0517-0960; 81284-611; 12079-2001; 62991-3131; 82920-045; 51662-1532; 63629-8599; 67457-197; 70860-400; 70860-407; 71335-1957; 81284-612; 14537-115; 65388-0156; 61990-0611; 67850-042; 38779-3211; 57218-951; 25021-415; 42571-314; 50090-5072; 63323-563; 68382-891; 72611-760; 12848-1004; 0013-1114; 69918-300; 49452-7877; 71052-166; 23155-166; 51754-0108; 62559-265; 72485-107; 38779-2794; 39822-1000
UNII 6T84R30KC1
Synonyms Tranexamic Acid | AMCHA | trans-4-(Aminomethyl)cyclohexanecarboxylic Acid | t-AMCHA | AMCA | Anvitoff | Cyklokapron | Ugurol | KABI 2161 | Spotof | Transamin | Amchafibrin | Exacyl
Chemical Information
Molecular Formula C8H15NO2
CAS Registry Number 701-54-2
SMILES C1CC(CCC1CN)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abdominal tenderness07.01.05.004--Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.018705%Not Available
Acute respiratory distress syndrome24.03.02.034; 10.02.01.067; 22.01.03.0010.003117%
Acute sinusitis22.07.03.013; 11.01.13.012--Not Available
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.021822%
Anaphylactic shock24.06.02.004; 10.01.07.0020.003117%Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Aneurysm24.02.01.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.014029%Not Available
Aortic dissection24.02.03.002--Not Available
Aphasia19.21.01.001; 17.02.03.0010.006235%
Arrhythmia02.03.02.0010.010911%Not Available
Arterial thrombosis24.01.01.0020.009352%Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.0020.029616%
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.0030.004676%
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.0100.003117%Not Available
Back pain15.03.04.0050.014029%
Blindness06.02.10.003; 17.17.01.0030.003117%Not Available
Blindness unilateral06.02.10.007; 17.17.01.0160.010911%Not Available
Bronchospasm22.03.01.004; 10.01.03.0120.003117%
Cardiac arrest02.03.04.0010.031175%
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.003117%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.009352%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages